Literature DB >> 6244085

Prognostic factors in Burkitt's lymphoma: importance of total tumor burden.

I Magrath, Y J Lee, T Anderson, W Henle, J Ziegler, R Simon, P Schein.   

Abstract

In 42 patients with African Burkitt's lymphoma, we have studied biochemical and clinical correlations with prognosis. Clinical stage and anti-EA titer were the best predictive factors, but lactic dehydrogenase (LDH) and uric acid (UA) concentrations also correlated with stage and prognosis, whereas lactic acid (LA), which was significantly elevated in Stage D, did not significantly correlated with prognosis or with LDH and UA levels. All of these factors with the possible exception of LA reflect the total body burden of tumor. We conclude that the tumor burden is the single most important prognostic factor in Burkitt's lymphoma, and that this is reflected directly by LDH and UA concentrations, and probably indirectly by anti-EA titer.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244085     DOI: 10.1002/1097-0142(19800315)45:6<1507::aid-cncr2820450634>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Appropriate investigation of inflammatory bowel disease in children.

Authors:  M D Stringer; T Randall; D P Rutter; S V Picton; J W Puntis
Journal:  J R Soc Med       Date:  1998-11       Impact factor: 5.344

2.  Paediatric wandering spleens in Malawi.

Authors:  E Broadis; M K Banda; E M Molyneux; E Borgstein
Journal:  Malawi Med J       Date:  2010-12       Impact factor: 0.875

3.  [Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

Authors:  B Steinke; J Mau
Journal:  Klin Wochenschr       Date:  1986-05-15

4.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth.

Authors:  H Shim; C Dolde; B C Lewis; C S Wu; G Dang; R A Jungmann; R Dalla-Favera; C V Dang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Gastrointestinal tumors in children: an analysis of 39 cases.

Authors:  M A Skinner; D A Plumley; J L Grosfeld; F J Rescorla; K W West; L R Scherer
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

Review 6.  Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.

Authors:  Ian T Magrath
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

7.  Serum lactic dehydrogenase predicts mortality in patients with AIDS and Pneumocystis pneumonia.

Authors:  M L Lipman; E Goldstein
Journal:  West J Med       Date:  1988-10

8.  Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.

Authors:  Twalib Ngoma; Melissa Adde; Muheez Durosinmi; Jessie Githang'a; Yetunde Aken'Ova; Jane Kaijage; Oluwagbemiga Adeodou; Jamilla Rajab; Biobele J Brown; Lorenzo Leoncini; Kikkeri Naresh; Martine Raphael; Nina Hurwitz; Patricia Scanlan; Ama Rohatiner; David Venzon; Ian Magrath
Journal:  Br J Haematol       Date:  2012-07-30       Impact factor: 6.998

9.  Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.

Authors:  Amolo S Asito; Erwan Piriou; Peter Sumba Odada; Nancy Fiore; Jaap M Middeldorp; Carole Long; Sheetij Dutta; David E Lanar; Walter G Jura; Collins Ouma; Juliana A Otieno; Ann M Moormann; Rosemary Rochford
Journal:  Infect Agent Cancer       Date:  2010-07-28       Impact factor: 2.965

10.  Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study.

Authors:  Geoffrey Buckle; Louise Maranda; Jodi Skiles; John Michael Ong'echa; Joslyn Foley; Mara Epstein; Terry A Vik; Andrew Schroeder; Jennifer Lemberger; Alan Rosmarin; Scot C Remick; Jeffrey A Bailey; John Vulule; Juliana A Otieno; Ann M Moormann
Journal:  Int J Cancer       Date:  2016-05-18       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.